Savara Inc.

Savara Inc.

SVRA·NASDAQ

$5.25

+1.9%
HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$1.08B
EPS-0.5300
P/E Ratio-9.91
Earnings Date08/06/2026

svra

Operating Income

Last Annual Value

-123.55M

3-Year CAGR

-47%

5-Year CAGR

-20%

10-Year CAGR

-12%

Savara Inc.

Savara Inc. Competitors Analysis of Operating Income

SVRA · NASDAQ
CompanyOperating Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
SVRA logo
Savara Inc.
NASDAQ:SVRA
-123.55M
N/AN/AN/A 
-303.63M
N/AN/AN/A
-53.84M
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
-79.89M
N/AN/AN/A
-155.60M
N/AN/AN/A
-111.29M
N/AN/AN/A
-132.76M
N/AN/AN/A
-243.43M
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
-165.01M
N/AN/AN/A
Savara Inc.

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.25, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

Intrinsic Value
Current Price: $5.25